Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is conducting a Phase 3 study titled A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa. The study aims to assess the disease activity and safety of Lutikizumab, an investigational drug, in treating moderate to severe Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition.
The study tests Lutikizumab, administered via subcutaneous injection, against a placebo. Lutikizumab is designed to alleviate the symptoms of HS by targeting specific inflammatory pathways.
This interventional study is randomized with a parallel assignment model and triple masking involving participants, care providers, and investigators. The primary purpose is treatment-focused, aiming to establish the efficacy and safety of Lutikizumab.
The study began on June 27, 2024, with primary completion expected by June 2025. The last update was submitted on June 24, 2025, indicating ongoing recruitment and study progress.
AbbVie’s study could significantly impact its stock performance and investor sentiment, particularly if Lutikizumab proves effective. The success of this study may position AbbVie favorably against competitors in the inflammatory disease treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.